United States Patent 5,767,251: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 5,767,251, titled "Recombinantly produced biologically active heterodimeric human fertility hormone," is a significant patent in the field of biotechnology and fertility treatments. This patent, assigned to Genzyme Corporation, covers a recombinant human fertility hormone, which is crucial for treating infertility issues. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
Invention Description
The patent describes a method for producing a biologically active heterodimeric human fertility hormone using recombinant DNA technology. This hormone is essential for fertility treatments, particularly in cases where natural hormone production is insufficient or impaired[2].
Claims
The patent includes several claims that define the scope of the invention. Key claims include:
- The recombinantly produced biologically active heterodimeric human fertility hormone.
- The process for producing this hormone using recombinant DNA techniques.
- The specific composition of the hormone, including its subunits and their interactions[2].
Scope of the Patent
Technology Field
The patent falls within the biotechnology and pharmaceutical fields, specifically focusing on fertility treatments. It involves advanced genetic engineering techniques to produce a functional human fertility hormone.
Applications
The hormone produced under this patent is used in medical treatments for infertility. It can be administered to patients to stimulate fertility processes, such as folliculogenesis in women[2].
Patent Claims Analysis
Claim Construction
The claims are constructed to cover the specific method of producing the hormone, the composition of the hormone itself, and its biological activity. This ensures that any similar methods or compositions would infringe on the patent.
Claim Scope
The scope of the claims is broad enough to encompass various aspects of the hormone's production and use but narrow enough to be specific and non-obvious. This balance is crucial for maintaining the patent's validity and enforceability.
Patent Landscape Analysis
Defining Scope and Keywords
To analyze the patent landscape around US 5,767,251, one must define the relevant technology field and keywords. In this case, keywords might include "recombinant human fertility hormone," "biologically active heterodimeric hormone," and "fertility treatments"[3].
Searching and Organizing Patents
Using databases such as the USPTO's Patent Public Search, Global Dossier, or international databases like the European Patent Office's esp@cenet, one can find relevant patents related to these keywords. Organizing these patents by filing date, assignee, and technology subcategories helps in understanding the evolution and distribution of related patents[1][3].
Identifying Trends and Key Players
The analysis reveals trends in patent filings, such as the increasing focus on recombinant DNA technology in fertility treatments. Key players in this field include biotechnology companies like Genzyme Corporation, as well as other pharmaceutical and biotech firms involved in similar research and development[3].
Analyzing Citations and Evolution
Studying how patents reference each other helps in understanding the impact and development of the technology. For example, if US 5,767,251 is frequently cited by other patents, it indicates its significance and influence in the field. This analysis can also reveal how the technology has evolved over time, including improvements and new applications[3].
Competitive Landscape
Key Patent Filers
The competitive landscape includes other companies and research institutions that have filed patents related to fertility hormones and recombinant DNA technology. Identifying these key filers helps in understanding the competitive environment and potential collaborations or challenges[3].
Geographical Distribution
The geographical distribution of patents in this field can highlight regions with high activity in fertility treatment research. This information can be crucial for strategic decisions regarding research collaborations, licensing opportunities, and market expansion[3].
Technical Gaps and Opportunities
The analysis can also identify technical gaps or areas where there is a lack of innovation. This information can guide research and development efforts towards unexplored or underdeveloped areas, providing opportunities for new inventions and market dominance[3].
Impact on the Market
Market Trends
The patent landscape analysis shows how the market for fertility treatments has evolved, including the adoption of recombinant DNA technology. This trend indicates a shift towards more advanced and effective treatments, driven by innovations like those covered by US 5,767,251[3].
Competitive Edge
Understanding the patent landscape around US 5,767,251 gives companies a competitive edge by identifying the most valuable patents, key players, and emerging technologies. This information can guide strategic decisions on research, licensing, and market positioning[3].
Expiry and Biosimilars
Patent Expiry
The patent for US 5,767,251 has expired, allowing for the development of biosimilars. This expiry opens up the market for generic versions of the hormone, potentially increasing accessibility and reducing costs for patients[2].
Biosimilar Development
The expiry of the patent enables other companies to develop biosimilars, which are biological products that are highly similar to the original product. This development can lead to increased competition and innovation in the fertility treatment market[2].
Conclusion
Key Takeaways
- Scope and Claims: US 5,767,251 covers the production and composition of a recombinant human fertility hormone.
- Patent Landscape: The landscape includes other patents related to fertility treatments and recombinant DNA technology, highlighting key players, trends, and geographical distribution.
- Competitive Edge: Understanding this landscape provides a competitive edge by identifying valuable patents, key players, and emerging technologies.
- Market Impact: The patent's expiry has opened the market for biosimilars, increasing accessibility and competition.
FAQs
1. What is the main invention described in US 5,767,251?
The main invention is a method for producing a biologically active heterodimeric human fertility hormone using recombinant DNA technology.
2. What are the key claims of the patent?
The key claims include the recombinantly produced hormone, the process for producing it, and the specific composition of the hormone.
3. How does the patent landscape analysis help in understanding the competitive environment?
It helps by identifying key players, trends, geographical distribution, and technical gaps, providing insights into the competitive landscape and emerging technologies.
4. What happens when a patent like US 5,767,251 expires?
When the patent expires, it allows for the development of biosimilars, increasing competition and potentially reducing costs for patients.
5. How can companies benefit from a patent landscape analysis around US 5,767,251?
Companies can benefit by gaining insights into the competitive landscape, identifying valuable patents, and making informed strategic decisions on research, licensing, and market positioning.
Cited Sources
- USPTO - Search for patents: https://www.uspto.gov/patents/search
- DrugPatentWatch - Biologic drug patents: https://www.drugpatentwatch.com/p/biologics/patent-claims/5767251
- Goldstein Patent Law - How to Do Patent Landscape Analysis: https://www.goldsteinpatentlaw.com/how-to-patent-landscape-analysis/
